Zoetis (ZTS), a leader in animal healthcare, is currently trading at a price-to-earnings ratio of just 19, significantly below its decade average of nearly 39. This decline comes amid challenges related to its osteoarthritis treatment, Librela, which has faced negative publicity due to reported side effects. Despite a 16% drop in Librela sales in 2025, Zoetis remains diversified, with the osteoarthritis franchise accounting for only 6% of total revenue.
The company managed to grow total sales by 2% in 2025 and has a robust pipeline, with 12 potential drugs expected to generate at least $100 million annually upon approval. Analysts project a 9.3% annual earnings growth for Zoetis over the next three to five years, indicating that the current valuation may present a buying opportunity for investors.
Given the long-term growth prospects and the potential for recovery in its reputation, investors may find Zoetis an attractive stock to hold as it navigates through its short-term challenges.
Source: fool.com